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The purpose of this study was to determine whether a rating of perceived exertion
scale (RPE) obtained during submaximal exercise could be used to predict peak
exercise capacity (METpeak) in coronary artery disease (CAD) patients. Angiographically
documented CAD patients (n = 124, 87% on β blockade) completed a symptom-limited
peak exercise test on a bicycle ergometer, reporting RPE values at every second load
on a scale of 6–20. Regression analysis was used to develop equations for predicting
METpeak. We found that submaximal METs at a workload of 60/75 W (for women and
men, respectively) and the corresponding RPE (METs/RPE ratio) was the most powerful
predictor of METpeak (r = 0.67, p < 0.0001). The final model included the submaximal
METs/RPE ratio, body mass index (BMI), sex, resting heart rate, smoking history, age,
and use of a β blockade (r = 0.86, p < 0.0001, SEE 0.98 METs). These data suggest that
RPE at submaximal exercise intensity is related to METpeak in CAD patients. The model
based on easily measured variables at rest and during “warm-up” exercise can reasonably
predict absolute METpeak in patients with CAD.
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INTRODUCTION
A large volume of data confirms the inverse dose–response
relationship between peak exercise capacity (METpeak) and all-
cause mortality in both male and female coronary artery disease
(CAD) patients irrespective of the use of β-blocking medica-
tion (Kavanagh et al., 2002, 2003), including patients with a
history of myocardial infarction, coronary artery bypass grafting
(CABG), percutaneous coronary intervention (PCI), and chronic
heart failure (Perk et al., 2012). Although being able to measure
METpeak by the “golden standard” method of a direct incremen-
tal symptom-limited peak exercise test, it may not be feasible
in everyday clinical settings for rehabilitation or in assessment
of functional capacity in CAD patients. Due to increasing con-
straints of time, equipment, patient safety and personnel needed
to carry out these tests, practical applications are typically sub-
maximal laboratory or field tests; e.g., a six-minute walking
test (Lipkin et al., 1986) is recommended for CAD patients
(Wijns et al., 2010). However, several adequate submaximal tests
that estimate METpeak are based on nomograms which pre-
dict METpeak, assuming a more or less linear increase in heart
rate simultaneously with increasing workload and oxygen uptake
Abbreviations: ACEI, angiotensin conversion enzymes inhibitor; AMI, acute
myocardial infarction; ARB, angiotensin receptor blocker; ACEI/ARB, patients
using at least one of them; BMI, body mass index; BP, blood pressure; CABG,
coronary artery bypass grafting; CCS, Canadian Cardiovascular Society angina
classification; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HR,
heart rate; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction;
LVMI, left ventricular mass index; METs, metabolic equivalents; n, number of
subjects; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percu-
taneous coronary intervention; T2D, type 2 diabetes; STEMI, ST segment elevation
myocardial infarction.
(Astrand and Ryhming, 1954; WHO, 1968). These tests are able
to predict METpeak in healthy subjects but not in CAD patients
due to the use of medication, particularly β blockades. Therefore,
accurate predictive estimates for METpeak in CAD patients are
warranted.
The ratings of perceived exertion (RPE) scale (Eston and
Williams, 1988) is widely accepted for obtaining a subjective esti-
mate of work intensity and as ameans of quantifying, monitoring,
and evaluating exercise intensity not only in healthy subjects, but
also in CAD patients (Pollock and Pels, 1984; Corra et al., 2010;
Scherr et al., 2013). The practical use of RPE for exercise prescrip-
tion also in patients with β blockades is well documented (Eston
and Connolly, 1996; Goss et al., 2011). Therefore, we hypothe-
sized that RPE during submaximal exercise can be used to predict
METpeak in CAD patients. The purpose of this study was firstly to
develop an equation for predicting METpeak using assessment of
RPE during submaximal exercise in CAD patients, and secondly
to validate the developed model and estimate the reproducibility
of the model in an independent sample of CAD patients.
MATERIALS AND METHODS
The patients in the test group (n = 124, 27 women) belong to
a larger Innovation to Reduce Cardiovascular Complications of
Diabetes at the Intersection study (ARTEMIS) taking place in
the Division of Cardiology at Oulu University Hospital (Oulu,
Finland) and the Department of Exercise and Medical Physiology
at Verve (Oulu, Finland). The ARTEMIS study is registered at
ClinicalTrials.gov, Record 1539/31/06. In addition, we recruited
from Oulu University Hospital an independent sample of volun-
teer CAD patients who had suffered acute coronary syndrome to
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serve as the validation group (n = 42, 12 women) and to test the
developed equation as a predictor of METpeak. The patients in
the validation group belong to a larger Effectiveness of Exercise
Cardiac Rehabilitation study (EFEX-CARE) taking also place in
the above mentioned institutions. The EFEX-CARE study is reg-
istered at ClinicalTrials.gov, Record NCT01916525. Demographic
characteristics of the study population are presented in Table 1.
The subjects were not allowed to eat or to drink coffee for 3 h
before the tests. Strenuous physical activity and alcohol consump-
tion were prohibited on the day of the tests and the preceding
day. The study was performed according to the Declaration of
Helsinki, the local research ethics committee of the Northern
Ostrobothnia Hospital District approved the protocol, and all the
subjects gave their written informed consent.
All the patients were diagnosed as having CAD, which
had been documented previously by coronary angiography. In
recruiting the CAD patients, the following exclusion criteria
were adhered: advanced age (>75 years), body mass index
(BMI) >40 kg/m2, NYHA class III or IV, left ventricular ejec-
tion fraction (LVEF) <40%, scheduled cardiac revascularization
therapy, unstable angina pectoris, severe peripheral atheroscle-
rosis, or inability to perform an exercise stress test, e.g., due to
musculoskeletal problems. Type 2 diabetes (T2D) was verified
according to the current criteria (Spies et al., 2005). Left ventric-
ular systolic function was assessed using 2-D echocardiography
(Vivid 7, GE Healthcare, Wauwatosa, WI, USA). Blood samples
were obtained for analysis of blood lipids, plasma glucose, and
glycated hemoglobin (HbA1c) levels (Oulu University Hospital,
Oulu, Finland).
The following protocol was performed in the Department
of Exercise and Medical Physiology at Verve (Oulu, Finland).
Blood pressure was measured (average of two measurements)
in a supine position after a 10-min resting period (Tango,
Sun-Tech, Raleigh, NC, USA). The patients performed an incre-
mental symptom-limited peak exercise test on a bicycle ergome-
ter (Monark Ergomedic 839 E, Monark Exercise AB, Vansbro,
Sweden) for assessment of METpeak. METpeak was used as an out-
come of maximal exercise capacity, since measurement of peak
oxygen consumption is not applied as daily routine in hospital.
One metabolic equivalent (MET) is the rate of energy expendi-
ture at rest (approximately 1 kcal per kilogram of body weight
per hour), which equates to oxygen consumption approximately
3.5ml/kg of body weight per minute for an average adult (Jette
et al., 1990). The test was started at 30 Watts (W) and the
work rate was increased by 15W in men and 10W in women
every minute until voluntary exhaustion or ST segment depres-
sion>0.2mV in electrocardiography (ECG). Prior to performing
the exercise test, the RPE scale was explained to each participant
by trained practitioners (Borg, 1982). RPE values were asked in
the 15 s before the end of every second workload on a scale of 6–
20 (Borg, 1970). METpeak was calculated from themean workload
during the last minute of the test. A 15-lead ECG (GE Healthcare,
CAM-14, Freiburg, Germany) was taken when the patients sat
1min on a bicycle without speaking, during the exercise and
10min after the exercise in a supine position.
After the predictive model was developed, we applied the equa-
tion to a seven-minute submaximal testing procedure with a
Table 1 | Demographic characteristics of study populations.
Test, Validation, p-value
n = 124 n = 42
Patients with T2D 69 (56%) 11 (26%) 0.001
Sex (M/F) 97 (78%)/ 30 (71%)/ 0.402
27 (22%) 12 (29%)
Age, years 62 ± 5 60 ± 10 0.105
Height, m 1.71 ± 0.8 1.70 ± 0.9 0.668
Weight, kg 83 ± 15 81 ± 18 0.435
BMI, kg/m2 28.3 ± 4.1 27.7 ± 4.6 0.391
Waist-hip ratio 0.99 ± 0.11 0.99 ± 0.15 0.924
Systolic BP, mmHg 146 ± 21 138 ± 22 0.040
Diastolic BP, mmHg 80 ± 10 76 ± 9 0.053
Current smokers 13 (10%) 8 (19%) 0.180
Depression score 5.0 ± 5.0 5.3 ± 5.4 0.755
HISTORY OF AMI
NSTEMI 40 (32%) 19 (45%) 0.262
STEMI 24 (19%) 11 (26%) 0.384
REVASCULARIZATION
PCI 73 (59%) 32 (76%) 0.063
CABG 27 (22%) 2 (5%) 0.010
CARDIAC FUNCTION
LVEF, % 66 ± 8 65 ± 7 0.366
LVMI 101 ± 23 102 ± 23 0.804
CCS class 1.2 ± 0.4 1.3 ± 0.5 0.237
PEAK EXERCISE TEST
Rest HR, bpm 59 ± 9 60 ± 8 0.700
Peak HR, bpm 130 ± 19 132 ± 19 0.665
Peak METs 7.1 ± 1.9 7.1 ± 2.0 0.941
Estimated peak mets 7.2 ± 1.6 7.2 ± 1.7 0.788
LABORATORY ANALYSES
HbA1c, % 6.3 ± 0.8 6.1 ± 1.1 0.151
Fasting plasma glucose, mmol/l 6.3 ± 1.4 5.7 ± 1.1 0.021
Total cholesterol, mmol/l 4.0 ± 0.8 4.0 ± 0.9 0.609
HDL cholesterol, mmol/l 1.2 ± 0.3 1.3 ± 0.3 0.731
LDL cholesterol, mmol/l 2.3 ± 0.6 2.4 ± 0.8 0.154
Triglycerides, mmol/l 1.5 ± 0.9 1.5 ± 0.7 0.999
MEDICATION
Oral antidiabetics 57 (46%) 10 (24%) 0.012
Insulin 10 (8%) 4 (10%) 0.755
Beta blockers 108 (87%) 35 (83%) 0.606
ACEI/ARB 74 (60%) 30 (71%) 0.200
Lipid lowering drugs 114 (92%) 40 (95%) 0.732
Anticoagulants 121 (98%) 41 (98%) 0.989
Calcium antagonists 26 (21%) 7 (17%) 0.658
Nitrates 29 (23%) 11 (26%) 0.683
Diuretics 38 (31%) 8 (19%) 0.167
bicycle (Monark 939E, Monark Exercise AB, Vansbro, Sweden).
Then we requested the patients in the validation group to visit
our laboratory at Verve 1 day before the measurement of METpeak
to perform a seven-minute submaximal test. Furthermore, we
asked the same patients to visit our laboratory 1 week after the
initial visit to perform submaximal test again to assess the repro-
ducibility of test. In the laboratory, first the patients sat 1min
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on a bicycle without speaking and their average resting heart rate
(Polar Electro, Kempele, Finland) was measured and recorded on
a Smart Card (HUR Oy, Kokkola, Finland). Then they started
cycling at 30W for women and 50W for men. As duringMETpeak
testing, the RPE scale was explained to each participant. In the 15 s
before the end of every one-minute workload the RPE value was
asked on a scale of 6–20 and recorded on the Smart Card. Based
on the reported RPE after each minute, workload was automati-
cally adjusted so that the given RPE value would be 13 at the end
of 5min of cycling. For example, if RPE after the first minute was
12, the second workload increased automatically by 5W to have
an RPE of 13 after the second minute. Finally, after the 5-minute
“warm up,” the patients sat one more minute on the bicycle with-
out speaking and their average recovery heart rate was measured
and recorded on the Smart Card. Then the collected data were
uploaded to a computer for calculation of predicted METpeak
(HUR Smart Card Software, HUR Oy, Kokkola, Finland).
Data normality was confirmed with the Kolmogorov-Smirnov
goodness-of-fit test. Differences between the test and validation
groups were analyzed by using independent-samples t tests and
chi-square tests. The data from the METpeak test were used to
develop equations for estimating METpeak using stepwise linear
regression analysis. All the significant demographic, medica-
tion, laboratory, leisure-time physical activity collected with the
questionnaire and echocardiographic variables from Spearman’s
correlation analyses and t tests were included in the linear regres-
sion analyses if their p-values were <0.05 to find the predictors
that maximized the R-value. The following parameters were
used to yield the best predictive equation: age, sex, BMI, hip
and waist size, smoking history, use of β blockade, T2D, heart
rate before cycling, and submaximal METs at a workload of
60/75W (for women and men, respectively) and correspond-
ing RPE (METs/RPE ratio). The METs/RPE ratio was defined
considering body weight and resting energy expenditure as fol-
lows: [(60/75 W× 12+ 3.5× body weight)/(3.5 × body weight)]
(Adams, 1990; ACSM, 1995).
The prediction of METpeak was compared with the measured
METpeak in both the test and validation groups using linear
regression analysis and standard error of the estimate (SEE).
A Bland-Altman analysis of measurement differences plotted
against mean values was used to assess the degree of agreement
(Bland and Altman, 1986) and to estimate the reproducibility of
the developed submaximal test. The statistical analyses were per-
formed using SPSS software, version 19.0 (SPSS Inc., Chicago,
USA). A p-value<0.05 was considered statistically significant.
RESULTS
Table 1 presents the demographic characteristics as well as the
measured and estimated METpeak values in both populations.
The groups did not differ in measured or estimated measured
METpeak. There were more T2D patients, higher systolic blood
pressure, and more revascularization by CABG in the test group
than in the validation group (p = 0.001, p = 0.040, and p =
0.010, respectively). Accordingly, fasting plasma glucose was
higher and there were more oral antidiabetic users in the test
group than in the validation group (p = 0.021 and p = 0.012,
respectively).
During the measurement of METpeak in the test group, sub-
maximal METs at a workload of 60/75W (55 ± 15% of mea-
sured Wpeak) was 4.0 ± 0.5 (59 ± 12% of measured METpeak)
and the corresponding RPE was 11.8 ± 2.1. The submaximal
METs/RPE ratio was the most powerful predictor of METpeak
(r = 0.67, p < 0.0001) explaining 44% of the variability in
METpeak. The final stepwise regression model correlated strongly
with that of METpeak after including the parameters in the fol-
lowing order: submaximal METs/RPE ratio, BMI, sex, heart rate
before cycling, smoking history, age, and use of β blockade
(r = 0.86, SEE 0.98 METs, p < 0.0001, Figure 1A). The follow-
ing best predictive equation explained 74% of the variability
in METpeak: 16.047+ 6.227 (submaximal/RPE ratio) − 0.178
(BMI) + 1.412 (sex) − 0.057 (heart rate before cycling) − 0.603
(smoking history) − 0.048 (age) − 0.605 (use of β blockade).
The mean difference between actual and predicted METpeak was
0.09 ± 1.00METs. The Bland-Altman plot found 94% of the
data points within the limits of agreement in the test group
(Figure 2A).
METpeak values collected from the seven-minute submaximal
testing procedure showed a strong association with the measured
METpeak (r = 0.77, p < 0.0001, SEE 1.38 METs, Figure 1B).
The mean difference between actual and predicted METpeak was
0.04± 1.37 METs. In the validation group, 98% of the data points
fell within the limits of agreement (Figure 2B). The difference
among twomeasurements of METs in the case of 26 patients, who
FIGURE 1 | Regression between predicted peak exercise capacity
(METpeak) and measured from the test (A) and validation (B) groups of
coronary artery disease patients.
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FIGURE 2 | Bland-Altman plot for predicted and measured METpeak in
both test (A) and validation (B) groups. The bold black lines indicate the
mean difference between measured and predicted METpeak and the bold
gray lines indicate the 95% limits of agreement (±2 SD).
FIGURE 3 | Differences among two measurements performed on each
of 26 patients as a function of their mean values for METs.
were able to participate the reproducibility study, are plotted as a
function of each subject’s mean value (r = 0.98, p < 0.0001, SEE
0.38 METs, Figure 3).
DISCUSSION
This study showed that RPE at submaximal exercise intensity is
related to measured METpeak in CAD patients. The data sup-
port the view that a regression model based on easily measured
variables at rest and during “warm-up” exercise can be used
to predict METpeak in patients with CAD in whom a peak
exercise test may not be feasible, and in repeated assessments
of exercise capacity after therapeutic interventions, e.g., dur-
ing rehabilitation programs, even on a weekly or monthly
basis.
Borg’s RPE scale is a widely used psycho-physical tool for
subjectively assessing work intensity during exercise. It is also
well documented that the RPE scale can be used to increase the
accuracy of monitoring and the prescription of exercise inten-
sity in the cardiac population using β blockade therapy (Pollock
and Pels, 1984; Eston and Connolly, 1996; Goss et al., 2011).
In the present study we found that a submaximal METs/RPE
ratio where an RPE value of approximately 12 was reached at an
intensity of 60/75W was associated most strongly with the mea-
sured METpeak. We decided to use a target RPE of 13 at the end
of 5min of cycling in the developed submaximal testing proce-
dure because it is well in line with the finding that an RPE of
14 might indicate fatigue if an incremental treadmill test is con-
tinued in CAD patients using β blockades (Goss et al., 2011).
Furthermore, according to the latest study by Scherr et al., train-
ing intensities corresponding to an RPE range of 11–13 (“fairly
light” to “somewhat hard”) should be recommended for CAD
patients (Scherr et al., 2013). Since safety during exercise testing
is very important, we feel the developed and validated submax-
imal test in this study meets these demands appropriately, as
well.
A 6-min walking test is a much-used, safe, and well-tolerated
method for assessing exercise capacity in cardiac patients (Gayda
et al., 2004; Wijns et al., 2010) and it also has prognostic value
in predicting cardiovascular events in CAD patients (Beatty
et al., 2012; Cacciatore et al., 2012). When the results of the
walking test are compared with measured peak exercise capac-
ity expressed as peak oxygen consumption in cardiac patients,
the correlation values have varied from 0.58 to 0.69, giving
an SEE normalized by mean peak oxygen consumption from
21 to 28% (Cahalin et al., 1996; Faggiano et al., 1997; Zugck
et al., 2000; Opasich et al., 2001). In the present study, we
found that the developed submaximal exercise test correlated
from 0.77 to 0.86 with the measured METpeak, indicating an
SEE from 14 to 19%. Bland-Altman analysis showed that only
a few values fell outside the 95% limits of agreement, which
suggests a good agreement between the actual and estimated
METpeak values. Furthermore, repeated tests performed for the
validation group showed that developed test model is highly
reproducible, which emphasize the use of this test as an indi-
vidual monitoring tool for exercise capacity. Taken together, the
present data support the concept that the estimated METpeak
values obtained from a submaximal exercise test are sufficiently
accurate, as they provide also an excellent fit with published
results.
It should be noted that the test and validation groups dif-
fered from each other in certain demographic characteristics, e.g.,
there were more revascularizations by CABG and a greater ten-
dency toward higher blood pressure in the test group than in
the validation group. Potentially, the differences are explained
by the fact that there was more T2D in the test group. The
patients in the test group belong to a larger ARTEMIS study,
where the aim is to gather two groups of patients; CAD patients
with and without T2D. The patients in the separate validation
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group were volunteers who had suffered from acute coronary syn-
drome. However, T2D was not related to measured METpeak and
it was not included in the predictive equation. Still, it remains
speculative if the minor discrepancy in the accuracy of the test
between groups (SEE 14 vs. 19%) is partly explained either by
the differences in demographic parameters or the implemented
submaximal testing procedure or both.
Based on the findings of the present study, the proposed sub-
maximal testing procedure can be useful for CAD patients also
in terms of motivation for physical activity and exercise training,
since the assessment of METpeak is available during the “warm-
up” of a single exercise session and no extra time for exercise
testing is needed. However, the ability of our test to follow changes
in METpeak during rehabilitation needs to be confirmed in fur-
ther studies. Another advantage of the developed test is the use
of guided self-regulated moderate exercise intensity expressed as
target RPE 13 at the end of the “warm up.” In this regard, a certain
learning effect of subjective feeling of moderate-intensity exercise
could be used to facilitate a transition from a supervised to a self-
guided exercise program and hopefully to serve as a contributing
factor for better adherence to a physical activity program. Finally,
almost all of the patients in our study were under continued β-
blocking medication, and cessation of β blockades usually is not
possible during exercise tests. Therefore, our results are valid and
could be generalized in clinical practice in CAD patients who are
under continued β-blocking medication.
In conclusion, the current study shows that Borg’s RPE is
a practical tool for assessing METpeak in secondary preventive
medicine. RPE at submaximal exercise intensity is related to
absolute METpeak in CAD patients. The data reveal that the rela-
tionships between RPE and exercise intensity together with easily
measured variables at rest and during “warm-up” exercise can
reasonably predict METpeak in patients with CAD.
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